Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Drug Versus Radioactive Treatment of Graves’ Disease – Metabolic Outcomes
source: Endocrine Society
year: 2016
authors: Elena Izkhakov, Mariana Yaron, Karen Michele Tordjman, Yona Greenman, Naftali Stern
summary/abstract:Background:
Weight gain is a common complaint in patients treated for Graves’ disease.We compared rates of weight gain, hypertension, glucose intolerance, and disturbance in lipid profile, following radioactive iodine (RAI) and antithyroid drug treatment in Graves’ patients.
Methods:
This is a cross-sectional study of patients with Graves’ disease treated at one institute between the years 2003-2010.Patients underwent physical examinations, which included height, weight and blood pressure (BMI calculated); 24 hour ambulatory blood pressure monitoring and blood measurements of fasting glucose, thyroid function and lipid profile. Additionally, we compared current to self reported past data regarding weight and BMI.
Results:
Of 113 patients, 68 (53 women) received RAI therapy and 45 (36 women) were treated with thioamides. Mean ages were 53 (95% CI: 50-56) and 48 (95% CI: 44-52) years, respectively, and median duration of disease: 5 (IQR: 4-6) and 6 (IQR: 3-8) years. After adjustment for sex, age and disease duration, body weight increased by a mean of 9.9% for RAI treated patients and 4.6% for medically treated subjects (P<0.025). Newly diagnosed dyslipidemia (detected after the diagnosis/treatment of Graves’ disease) was more common in RAI-treated than in medically treated patients (37.7% vs 17.1%; P<0.028). Further, RAI treated patients had a higher number of components of the metabolic syndrome compared to the drug treated patients (2.0 vs 1.4; p<0.018)
Conclusions:
The results of this study are consistent with some previously reported data concerning the outcome of the main two modalities of the treatment of hyperthyroidism. The key findings in our study are that compared to medically treated patients with Graves’ disease, RAI-treated subjects with the same disease experienced a significantly larger increase of the body weight and had a higher rate of new-onset dyslipidemia with significantly higher number of components of the metabolic syndrome.
read more
myBinderRelated Content
-
Julian Perry, MDJulian Perry, MD received his medical de...
-
Graves’ Disease Pharmacotherapy in Women of Reproductive AgeGraves' disease is an autoimmune disorde...
-
Thyroid Surgery for Graves’ Disease and Graves’ OphthalmopathyBackground: Graves' disease is an autoi...
-
Basic Understanding About Graves’ DiseaseWhat Is Graves’ Disease? Graves’ di...
-
Comparison of Endoscopic and Conventional Open Thyroidectomy for Graves’ Disease: A Meta-analysisBackground: Despite experience with the...
-
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a ...Objective: Male gender is considered an...
-
External Validation of the GREAT Score to Predict Relapse Risk in Graves’ Disease: Results from a Multicenter,...Context: First-line treatment in Graves...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google